Congruence Therapeutics
PrivateLast Round
VC Round
Mar 19, 2026
Total Funding Raised
$98M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Congruence Therapeutics operates in Healthcare & Life Sciences and is based in Montreal. Its latest recorded funding round was a VC Round in March 2026.
Congruence Therapeutics is a biotechnology company that develops small molecule correctors to rescue aberrant protein function in protein misfolding diseases using a proprietary computational drug discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Congruence Therapeutics Comparables
Compare Congruence Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gain Therapeutics Inc | 80% | |
| Atlas Molecular Pharma | 79% | |
| Protego Biopharma | 79% |
For institutional investors. Book with your work email.
Congruence Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Mar 19, 2026 | ||||
| Early Funding | Sep 4, 2025 | ||||
| Grant | Jul 24, 2025 | ||||
| Series A Extension | Mar 6, 2023 | ||||
| Series A | Feb 8, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Congruence Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Investissement Québec | Early Funding, Series A, VC Round, Series A Extension |
| Amplitude Ventures | Early Funding, VC Round, Series A Extension, Series A |
| Fonds de solidarité FTQ | Early Funding, VC Round, Series A Extension, Series A |
| BDC Capital | Early Funding, VC Round |
| OrbiMed | Early Funding, Series A, VC Round, Series A Extension |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
| Alexandria Venture Investments | Early Funding |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 9, 2026
Attending the 25th Annual Needham Virtual Healthcare Conference.
- Apr 8, 2026
Launched Revenir™ for identifying novel binding sites.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 23, 2026
Congruence announces an oral presentation at the European Respiratory Society (ERS) Alpha-1 Antitrypsin Conference 2026 in Spain on Oct 23-24th '26, where its scientists present preclinical data on CGX-195 for alpha-1 antitrypsin deficiency.
For institutional investors. Book with your work email.
Congruence Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Congruence Therapeutics's valuation, stock price, and market status.
Is Congruence Therapeutics a public or private company?
Congruence Therapeutics is a private company.
What is the current stock price of Congruence Therapeutics?
Congruence Therapeutics is a private company, so its shares have no public market price. Caplight tracks Congruence Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Congruence Therapeutics worth (valuation)?
Valuation information for Congruence Therapeutics is not publicly available.
Can I buy Congruence Therapeutics stock?
Congruence Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Congruence Therapeutics's last funding round?
Congruence Therapeutics's most recent funding round was VC Round on March 19, 2026.
Who are the main investors in Congruence Therapeutics?
Key investors in Congruence Therapeutics include Amplitude Ventures, Fonds de solidarité FTQ, The Michael J. Fox Foundation for Parkinson's Research, BDC Capital Management, Dimension.
Will Congruence Therapeutics IPO soon?
No public IPO plans have been announced for Congruence Therapeutics.
How can I track Congruence Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Congruence Therapeutics's shares on secondary markets.